Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window. The Company’s CT-95 is being developed as a therapy for advanced cancers associated with mesothelin (MSLN) expression.

• Revenue in USD (TTM)0.00
• Net income in USD-18.57m
• Incorporated2015
• Employees5.00

• Location
  Context Therapeutics Inc2001 Market Street, Suite 3915 Unit #15PHILADELPHIA 19103United StatesUSA
• Phone+1 (267) 225-7416
• Fax+1 (302) 655-5049
• Websitehttps://www.contexttherapeutics.com/